Longitudinal Analysis of Amyloid PET and Brain MRI for Predicting Conversion from Mild Cognitive Impairment to Alzheimer's Disease: Findings from the ADNI Cohort.

IF 2.2 4区医学 Q2 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Tomography Pub Date : 2025-03-19 DOI:10.3390/tomography11030037

Do-Hoon Kim

{"title":"Longitudinal Analysis of Amyloid PET and Brain MRI for Predicting Conversion from Mild Cognitive Impairment to Alzheimer's Disease: Findings from the ADNI Cohort.","authors":"Do-Hoon Kim","doi":"10.3390/tomography11030037","DOIUrl":null,"url":null,"abstract":"Background/objectives: This study aimed to investigate the predictive power of integrated longitudinal amyloid positron emission tomography (PET) and brain magnetic resonance imaging (MRI) data for determining the likelihood of conversion to Alzheimer's disease (AD) in patients with mild cognitive impairment (MCI).Methods: We included 180 patients with MCI from the Alzheimer's Disease Neuroimaging Initiative, with baseline and 2-year follow-up scans obtained using F-18 florbetapir PET and MRI. Patients were categorized as converters (progressing to AD) or nonconverters based on a 6-year follow-up. Quantitative analyses included the calculation of amyloid burden using the standardized uptake value ratio (SUVR), brain amyloid smoothing scores (BASSs), brain atrophy indices (BAIs), and their integration into shape features. Longitudinal changes and receiver operating characteristic analyses assessed the predictive power of these biomarkers.Results: Among 180 patients with MCI, 76 (42.2%) were converters, who exhibited significantly higher baseline and 2-year follow-up values for SUVR, BASS, BAI, and shape features than nonconverters (p < 0.001). Shape features demonstrated the highest predictive accuracy for conversion, with areas under the curve of 0.891 at baseline and 0.898 at 2 years. Percent change analyses revealed significant increases in brain atrophy; amyloid deposition changes showed a paradoxical decrease in converters. Additionally, strong associations were observed between longitudinal changes in shape features and neuropsychological test results.Conclusions: The integration of amyloid PET and MRI biomarkers enhances the prediction of AD progression in patients with MCI. These findings support the potential of combined imaging approaches for early diagnosis and targeted interventions in AD.","PeriodicalId":51330,"journal":{"name":"Tomography","volume":"11 3","pages":""},"PeriodicalIF":2.2000,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11945403/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Tomography","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/tomography11030037","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}

引用次数: 0

Abstract

Background/objectives: This study aimed to investigate the predictive power of integrated longitudinal amyloid positron emission tomography (PET) and brain magnetic resonance imaging (MRI) data for determining the likelihood of conversion to Alzheimer's disease (AD) in patients with mild cognitive impairment (MCI).

Methods: We included 180 patients with MCI from the Alzheimer's Disease Neuroimaging Initiative, with baseline and 2-year follow-up scans obtained using F-18 florbetapir PET and MRI. Patients were categorized as converters (progressing to AD) or nonconverters based on a 6-year follow-up. Quantitative analyses included the calculation of amyloid burden using the standardized uptake value ratio (SUVR), brain amyloid smoothing scores (BASSs), brain atrophy indices (BAIs), and their integration into shape features. Longitudinal changes and receiver operating characteristic analyses assessed the predictive power of these biomarkers.

Results: Among 180 patients with MCI, 76 (42.2%) were converters, who exhibited significantly higher baseline and 2-year follow-up values for SUVR, BASS, BAI, and shape features than nonconverters (p < 0.001). Shape features demonstrated the highest predictive accuracy for conversion, with areas under the curve of 0.891 at baseline and 0.898 at 2 years. Percent change analyses revealed significant increases in brain atrophy; amyloid deposition changes showed a paradoxical decrease in converters. Additionally, strong associations were observed between longitudinal changes in shape features and neuropsychological test results.

Conclusions: The integration of amyloid PET and MRI biomarkers enhances the prediction of AD progression in patients with MCI. These findings support the potential of combined imaging approaches for early diagnosis and targeted interventions in AD.

查看原文本刊更多论文

淀粉样蛋白PET和脑MRI的纵向分析预测从轻度认知障碍到阿尔茨海默病的转变：来自ADNI队列的发现。

背景/目的：本研究旨在调查淀粉样蛋白正电子发射断层扫描（PET）和脑磁共振成像（MRI）综合纵向数据对轻度认知障碍（MCI）患者转为阿尔茨海默病（AD）可能性的预测能力：我们纳入了阿尔茨海默病神经影像学倡议（Alzheimer's Disease Neuroimaging Initiative）中的180名MCI患者，并使用F-18氟贝他匹尔正电子发射计算机断层扫描（F-18 florbetapir PET）和核磁共振成像（MRI）对其进行基线扫描和2年随访扫描。根据6年的随访结果，患者被分为转化者（进展为AD）和非转化者。定量分析包括使用标准化摄取值比（SUVR）计算淀粉样蛋白负荷、脑淀粉样蛋白平滑化评分（BASS）、脑萎缩指数（BAI），并将其整合到形状特征中。纵向变化和接收器操作特征分析评估了这些生物标志物的预测能力：在 180 名 MCI 患者中，76 人（42.2%）为转换者，他们的 SUVR、BASS、BAI 和形状特征的基线值和 2 年随访值均显著高于非转换者（p < 0.001）。形状特征对转化的预测准确率最高，基线曲线下面积为 0.891，2 年后为 0.898。百分比变化分析显示，脑萎缩程度显著增加；淀粉样蛋白沉积变化显示，转化者的脑萎缩程度反而有所下降。此外，还观察到形状特征的纵向变化与神经心理测试结果之间存在密切联系：淀粉样蛋白 PET 和 MRI 生物标记物的整合增强了对 MCI 患者的 AD 进展的预测。这些发现支持了联合成像方法在早期诊断和有针对性地干预AD方面的潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Tomography Medicine-Radiology, Nuclear Medicine and Imaging

CiteScore

2.70

自引率

10.50%

发文量

222

期刊介绍： TomographyTM publishes basic (technical and pre-clinical) and clinical scientific articles which involve the advancement of imaging technologies. Tomography encompasses studies that use single or multiple imaging modalities including for example CT, US, PET, SPECT, MR and hyperpolarization technologies, as well as optical modalities (i.e. bioluminescence, photoacoustic, endomicroscopy, fiber optic imaging and optical computed tomography) in basic sciences, engineering, preclinical and clinical medicine. Tomography also welcomes studies involving exploration and refinement of contrast mechanisms and image-derived metrics within and across modalities toward the development of novel imaging probes for image-based feedback and intervention. The use of imaging in biology and medicine provides unparalleled opportunities to noninvasively interrogate tissues to obtain real-time dynamic and quantitative information required for diagnosis and response to interventions and to follow evolving pathological conditions. As multi-modal studies and the complexities of imaging technologies themselves are ever increasing to provide advanced information to scientists and clinicians. Tomography provides a unique publication venue allowing investigators the opportunity to more precisely communicate integrated findings related to the diverse and heterogeneous features associated with underlying anatomical, physiological, functional, metabolic and molecular genetic activities of normal and diseased tissue. Thus Tomography publishes peer-reviewed articles which involve the broad use of imaging of any tissue and disease type including both preclinical and clinical investigations. In addition, hardware/software along with chemical and molecular probe advances are welcome as they are deemed to significantly contribute towards the long-term goal of improving the overall impact of imaging on scientific and clinical discovery.